Elsevier

Atherosclerosis

Volume 240, Issue 2, June 2015, Pages 490-496
Atherosclerosis

The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial

https://doi.org/10.1016/j.atherosclerosis.2015.03.039Get rights and content

Highlights

  • We evaluated the effect of p38MAPK inhibitor, BMS-582949, on arterial inflammation.

  • Subjects with known ASCVD were randomized to BMS-582949, placebo, or atorvastatin.

  • We demonstrate that treatment with BMS-582949 did not reduce arterial inflammation.

  • Intensification of statin therapy (positive control) reduced arterial inflammation.

Abstract

Objectives

This study evaluated the effect of p38 mitogen-activated protein kinase (p38MAPK) inhibitor, BMS-582949, on atherosclerotic plaque inflammation, using 18FDG-PET imaging. p38MAPK is an important element of inflammatory pathways in atherothrombosis and its inhibition may lead to reduced inflammation within atherosclerotic plaques.

Methods

Subjects with documented atherosclerosis (n = 72) on stable low-dose statin therapy and having at least one lesion with active atherosclerotic plaque inflammation in either aorta or carotid arteries were randomized to BMS-582949 (100 mg once daily), placebo, or atorvastatin (80 mg once daily), for 12 weeks. Arterial inflammation was assessed using 18FDG-PET/CT imaging of the carotid arteries and aorta. Uptake of arterial 18FDG was assessed as target-to-background ratio (TBR): 1) as a mean of all slices of the index vessel, and 2) within active slices of all vessels (AS: which includes only slices with significant inflammation (TBR ≥ 1.6) at the baseline).

Results

Treatment with BMS-582949 did not reduce arterial inflammation relative to placebo, (ΔTBR index: 0.10 [95% CI: −0.11, 0.30], p = 0.34; ΔTBR AS: −0.01 [−0.31, 0.28], p = 0.93) or hs-CRP (median %ΔCRP [IQR]: 33.83% [153.91] vs. 16.71% [133.45], p = 0.61). In contrast, relative to placebo, statin intensification was associated with significant reduction of hs-CRP (%ΔCRP [IQR]: −17.44% [54.68] vs. 16.71% [133.45], p = 0.04) and arterial inflammation in active slices (ΔTBRAS = −0.24 [95% CI: −0.46, −0.01], p = 0.04).

Conclusions

The findings of this study demonstrates that in stable atherosclerosis, 12 weeks of treatment with BMS-582949 did not reduce arterial inflammation or hs-CRP compared to placebo, whereas intensification of statin therapy significantly decreased arterial inflammation.

Introduction

Cardiovascular disease (CVD) is the leading cause of mortality worldwide [1]. Atherothrombosis is the primary cause of ischemic CVD and is caused by the accumulation of inflammatory cells, which culminates in the development of complex atherosclerotic plaques, precursors of acute coronary syndromes [2]. Currently, the mainstay for the preventive treatment of atherothrombosis is lipid lowering, mainly using statins, whereby anti-inflammatory effects are believed to contribute to their mechanism of action [3], [4]. Statin usage in secondary prevention trials has been shown to produce about a 30% reduction in events, which leaves approximately 70% of the events unattenuated [5]. Novel treatments are therefore needed to address the residual risk.

Inflammation is a critical component in the pathogenesis of atherothrombosis [6] and represents an attractive therapeutic target [7]. Novel anti-inflammatory therapeutics have been developed targeting specific intracellular protein kinases to suppress key mediators of inflammation. One approach is targeted towards the inhibition of the p38 mitogen-activated protein kinases (P38 MAPKs) [8]. P38 MAPKs are members of a key signaling pathway responsible for the cellular response to various extracellular stresses, which function to orchestrate a broader cellular response [9]. Activation of P38 MAPKs is linked to increased production of inflammatory mediators such as proinflammatory cytokines, prostaglandins/prostacyclins and matrix metalloproteinases [9]. In humans, the inhibition of p38 MAPK has been demonstrated to improve nitric oxide mediated vasodilation accompanied by a reduction in systemic inflammation [10], and a decrease in neointima formation and systemic inflammatory markers, after percutaneous coronary intervention [11].

Quantification of inflammation in atherosclerotic plaques with 18FDG-PET is based on the metabolic activity of plaque macrophages, which avidly take up 18F-fluordeoxyglucose (18FDG). 18F-fluordeoxyglucose then becomes metabolically trapped and can be detected non-invasively with positron emission tomography (PET) [12], [13]. This technique has been demonstrated as a reproducible imaging modality for the evaluation of inflammation in atherosclerotic plaques in both animal and human studies and allows for non-invasive efficacy assessment of therapeutic interventions [14], [15], [16], [17], [18].

Recently, the dual αβ subtype, p38 MAPK inhibitor, losmapimod (7.5 mg once daily for 12 weeks), was associated with a modest reduction in arterial inflammation in stable atherosclerosis subjects, as measured by 18FDG-PET/CT [19]. Furthermore, a significant reduction of inflammation in visceral fat and a persistent reduction in high sensitivity C-reactive peptide (hsCRP) was observed. In contrast to losmapimod, BMS-582949 is a novel highly selective p38α MAPK inhibitor [20]. In the current study, we sought to evaluate the effect of BMS-582949 on arterial inflammation in subjects with stable atherosclerosis, and to compare this potential anti-inflammatory action to the effect of statin intensification (using high-dose atorvastatin in subjects already on low-dose statins at baseline).

Section snippets

Methods

This 12 week, randomized, partially double-blinded study (double-blind for BMS-582949 and placebo, open label administration of atorvastatin 80 mg) was conducted at 17 US Centers in compliance with the principles of the Declaration of Helsinki and according to Good Clinical Practice guidelines (www.clinicaltrails.gov, NCT00570752). The protocol was reviewed and approved by each center's institutional review board and all participants provided written informed consent prior to any study

Subject data

Subject demographics and characteristics at baseline were generally comparable across treatment groups as shown in Table 1. A total of 72 subjects were randomized. Ten subjects discontinued early due to adverse effects, withdrawal of consent, protocol derivation, or other reason and 53 subjects provided evaluable imaging data at 12 weeks (Fig. 1).

Effects on atherosclerotic plaque activity

Results of various image analysis endpoints are summarized in Table 2. The analysis evaluating the change from baseline TBR within all slices of the

Discussion

The present study demonstrates that p38 MAPK inhibitor, BMS-582949, is safe and well-tolerated in subjects with stable atherosclerotic disease receiving statin therapy. However, it is not associated with attenuation of atherosclerotic inflammation and, though in a relatively small number of subjects and short treatment duration, it was not associated with a reduction in systemic inflammatory biomarkers.

In the previously mentioned 18FDG-PET/CT trial evaluating another p38 MAPK inhibitor,

Funding

This study is sponsored by Bristol-Myers Squibb.

Acknowledgments

We thank all of the BMS-582949 investigators, their staff personnel, and subjects that participated in this trial. The statistical analysis was conducted with consult from Harvard Catalyst which is supported by National Center for Research Resources and the National Center for Advancing Translational Sciences (NIH Award UL1 TR001102).

References (27)

Cited by (63)

  • Rapid reduction in plaque inflammation by sonodynamic therapy inpatients with symptomatic femoropopliteal peripheral artery disease:A randomized controlled trial

    2021, International Journal of Cardiology
    Citation Excerpt :

    Furthermore, their peak walking time (PWT) should be at least 2, but not more than 11 min on the graded treadmill test using the Gardner protocol [16]. Participants were on the stable use of statins for at least 6 weeks prior to 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) screening to exclude the change in low-density lipoprotein levels during the study [17]. Permitted statin drugs/doses were atorvastatin 20 mg, simvastatin 40 mg, rosuvastatin 10 mg, pravastatin 40 mg, fluvastatin 80 mg, or lovastatin 40 mg.

  • Molecular Imaging of Atherosclerosis

    2021, Molecular Imaging: Principles and Practice
View all citing articles on Scopus
1

Contributed equally to this work.

View full text